

CURRICULUM VITAE - PAUL CLIFFORD ADAMS

Paul Clifford Adams

Date of Birth: January 18, 1956

Canadian, married, 3 children.

Current Address - Department of Medicine,
University Hospital,
339 Windermere Road,
London, Ontario,
Canada N6A 5A5.
Ph. 519-685-8500 ext 35375.
FAX 519-663-3549
Email - padams@uwo.ca

Experience

Chief, Division of Gastroenterology, University of Western Ontario (University Hospital, Victoria Hospital, St Joseph's Health Centre) – July 2007 – June 2017
Chief, Division of Gastroenterology, University Hospital, September 2002 - 2007
Professor of Medicine, University of Western Ontario, London Health Sciences Centre – University Campus, London, Ontario, Canada - July 1998
Professor of Pathology (cross-appointment), University of Western Ontario, London Health Sciences Centre – University Campus, London, Ontario, Canada – October 2000
Associate Professor of Medicine, University of Western Ontario, University Hospital, London, Ontario, Canada - July 1994 – June 1998
Visiting Professor - Clinique des maladies du foie, CHRU Pontchaillou, INSERM U49, Universite de Rennes, France - July 1995 - January 1996.
Assistant Professor of Medicine, University of Western Ontario, University Hospital, London, Ontario, Canada, July 1988 - June 1994
Visiting Research Fellow, Liver Research Unit, San Francisco General Hospital, San Francisco, California March - April 1988.
Research Fellow, Liver Research Unit, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia. January 1986 - January 1988.
Gastroenterology Fellow, University of California, San Francisco. July 1983 - June 1985.
Senior Medical Resident, Mount Sinai Medical Center, New York, N.Y. July 1982 - June 1983.
Medical Resident, Toronto Western Hospital, Toronto, Ontario, Canada. July 1980 - June 1982.

Education

M.D., Queens University, Kingston, Ontario, 1976 - 1980.
Arts and Science undergraduate, Queens University, Kingston, Ontario, 1974 - 1975.
Trinity College School, Port Hope, Ontario 1970 - 1974

Certifications

Diplomate of the American Board of Gastroenterology - November 1985
Diplomate of the American Board of Internal Medicine - September 1983
Fellow of the Royal College of Physicians (Internal Medicine) - November 1984
Diplomate of the National Board of Medical Examiners - May 1981
Licencee of the Medical College of Canada - May 1980

Awards and Scholarships

Honorary Fellowship of the American Association for the Study of Liver Diseases (FAASLD) - September 2014
 Honorary Fellowship for Distinction - Royal College of Physicians of Ireland 2013
 Canadian Liver Foundation / CASL Gold Medal – February 2010
 Sherbaniuk-Wensel Lectureship Award – University of Alberta, October 2009
 Faculty of Medicine and Dentistry- Dean’s Award of Excellence – Multi-Organ Transplant Team Award – 2008
 Norman Grace Lectureship – Harvard University – Brigham and Women’s Hospital, May 2008
 Joseph Gilbert Research Contribution of the Year Award – Lawson Health Research Institute – 2007
 Hans Fromm Memorial Lectureship – Dartmouth University, New Hampshire, October 2007
 Faculty of Medicine and Dentistry- Dean’s Award of Excellence – Research Team Award – 2005
 Bushell Lectureship – Highest Award of the Australian Gastroenterology Association – 2004
 Commemorative Medal for the Golden Jubilee of Her Majesty Queen Elizabeth II - 2002
 Faculty of Medicine and Dentistry - Dean's Award of Excellence (Research) - 1999
 Department of Medicine – University of Western Ontario – Senior Research Award – 1998
 Special Achievement Award - French Hemochromatosis Association - June 1997
 Canadian Association for the Study of the Liver Junior Investigator Award - 1992
 Ministry of Health of Ontario Health Research Personnel Fellowship - June 1985 (declined).
 Alice Waddington Scholarship of Medicine - Queens University 1980.
 Admission scholarship Queens University 1974.
 Admission scholarship Trinity College, University of Toronto, 1974 (declined).

Research Grants

External Awards - Principal Investigator

- Canadian Liver Foundation - 'Iron metabolism and hemochromatosis' - \$ 70,000 - CLF Fellowship - January 1986 - January 1988
- Medical Research Council of Canada operating grant - 'Isolation of Hepatic Ferritin Receptor' \$93,000 -1989 -1992.
- Ministry of Health of Ontario - Career Scientist Personnel Award - 'Iron metabolism and hemochromatosis', \$220,000 - 1988 - 1993
- Canadian Liver Foundation Establishment Grant (declined) - 'Isolation of Hepatic Ferritin Receptor', \$80,000 - July 1989
- Physicians Services Incorporated (PSI) Foundation Research Grant (Grant DR) - 'Mucosal iron in the control of iron absorption in a rat intestinal transplant model', \$35,000 -July 1989 - July 1990
- Ministry of Health of Ontario Equipment Grant - \$7,850 - April 1989
- Canadian Liver Foundation Student Fellowship Grant (supervisor) - 'Monocyte ferritin in hemochromatosis', \$3,900 - July 1990
- Schering Canada (Ghent CN) - 'Interferon therapy in the treatment of chronic viral hepatitis', \$112,000 - August 1992 - August 1994.

- PSI Foundation - 'Localization of the hemochromatosis gene - phase 1' - \$25,000 - September 1992 - September 1994
- PSI Foundation (Bierbrier G, Feldman RD) - 'Adrenergic response in cirrhosis' - \$14,500 - December 1992 - July 1993
- Canadian Liver Foundation (Flanagan PR) - 'Iron Regulatory Factor in Hemochromatosis' - \$ 90,000 - October 1993 - October 1995
- Royal College of Physicians and Surgeons of Canada - 'Localization of the hemochromatosis gene' - \$ 10,500 - Detweiler Fellowship - July 1995
- Medical Research Council of Canada / Centre National de la Recherche Scientifique International Scientific Exchange Award - "Localization of the hemochromatosis gene" - \$11,000 - July 1995
- Center for Disease Control - Atlanta, USA (Edwards C, Barton J) - Natural history and response to therapy in persons with iron overload - \$US 70,000 - July 1996
- PSI Foundation - Blood donor screening for hereditary hemochromatosis - \$140,000 - October 1996
- PSI Foundation - Prevalence of C282Y mutation in end-stage liver disease - \$14,500 - September 1997
- Medical Research Council of Canada - Genotyping for hemochromatosis - \$ 113,000 - March 1998
- Canadian Association of Gastroenterology - Summer student fellowship (J Hajek) Nramp2 in hemochromatosis - \$5000 - July 1998
- Medical Research Council of Canada - Psychosocial impact of genetic testing for hemochromatosis - \$ 37,000 - March 1999
- NIH - National Heart, Lung and Blood Institute (Bethesda, MD) – Principal investigator – **HE**mochromatosis and **IR**on overload **S**creening study (**HEIRS**) – February 2000 - NIH-NHLBI-HC-99-04 – Total project \$ US 34,000,000, UWO - \$ US 2,476,874
- Canadian Liver Foundation (S Chakrabarti) – Iron transport genes and proteins in hemochromatosis – \$120,000 – September 2000
- Canadian Institute of Health Research – Utility assessment in Hepatitis C infection (Co-investigator, P Marotta, B Feagan) – January 2001 – \$120,000
- Canadian Blood Services – Hemochromatosis patients as voluntary blood donors – August 2001 - \$38,000
- National Institute of Health (Bethesda, MD) – ELSI Branch – National Genetics Institute – Ethical, Social and Legal Implications of Genetic testing for hemochromatosis – Supplemental Award – October 2001 - \$100,000.
- Canadian Association for the Study of the Liver – Hpcidin and hemochromatosis – Fellowship Award (D Thorburn) - \$55,000 – January 2003

- Canadian Liver Foundation (B Rutt) – Quantitation of liver iron concentration using MRI – September 2003 - \$120,000
- NIH - National Heart, Lung and Blood Institute (Bethesda, MD) – Principal investigator – **HE**mochromatosis and **IR**on overload **S**creening study (**HEIRS**) – February 2005 - NIH-NHLBI-HC-99-04 – Renewal extension - \$US 203,918
- NIH - National Heart, Lung and Blood Institute (Bethesda, MD) – Principal investigator – **HE**mochromatosis and **IR**on overload **S**creening study (**HEIRS**) – February 2006 - NIH-NHLBI-HC-99-04 – Renewal extension - \$US 64,583
- NIH – NHLBI/NIDDK (Bethesda, MD) – Iron Status: A Pathway Analysis in Multiple Ethnicities. (McLaren C, PI and the HEIRS Study Group, R01 HL083328-01A1) – Jan 2006 – Dec 2010 - \$US 1,746,669 direct costs
- Canadian Institute of Health Research (CIHR) - Perfusion and lipid imaging with a liver specific CT contrast agent to detect progression of cirrhosis to hepatocellular carcinoma (Lee T, Adams PC, Chakrabarti S),- \$ 306,693 January 2007 – 2010.
- Canadian Liver Foundation – Evaluation of Phlebotomy as a treatment of non-alcoholic fatty liver disease (Beaton M, Adams PC, Levstik M, Marotta P) - \$99,975 January 2009 – January 2011.
- Canadian Institute of Health Research (CIHR)- Physician billing costs attributable to ambiguous genetic tests (PI - Adams PC, Speechley M) - \$24,500 November 2008
- Simultaneous Non-Invasive Quantification of Hepatic Steatosis and Iron Concentration with MRI – Principal Investigators (Adams PC, Beaton M, McKenzie C) - Physician Services Incorporated Foundation - \$49,500 December 2008
- National Institute of Health - PAR-08-181 (R24 DK093433-01), Genetic Modifiers of Iron Status in Hemochromatosis *HFE* C282Y Homozygotes (Co-PI, Adams PC, McLaren CE, McLaren, GD, Barton JC, Gurrin L, Subramaniam N, Phatak P) Approved Sept 2011, \$375,835 USD
- National Institute of Health - R24 Genetic Modifiers of Iron Status in Hemochromatosis *HFE* C282Y Homozygotes (Co-PI, Adams PC, McLaren CE, McLaren, GD, Barton JC, Gurrin L, Subramaniam N, Phatak P, R24DK099846-01A1) September 2014 - September 2018 - \$2,044,286 USD

Current Participant in international Clinical Drug Trials (Principal investigator - UWO)

- Gilead - A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
- Gilead - A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Non-Alcoholic Fatty Liver Disease
- Glaxo Smith Kline – A double-blind, randomized, placebo-controlled multi-center, phase II, parallel dose-ranging study to assess the antifibrotic activity of G1262570 in chronic hepatitis C subjects with hepatic fibrosis who have failed antiviral therapy – November 2005

- Novartis – A phase 1/II open label, dose-escalation trial to explore the safety and efficacy of ICL670 (Exjade) in patients with iron overload resulting from hereditary hemochromatosis

Participant in 8 other pharmaceutical studies on viral hepatitis as co-investigator

Publications

Peer reviewed publications

1. Lloyd D., **Adams PC**, Sinclair N., Stiller C.R., Valberg L.S. HLA Antigens as markers of abnormal iron metabolism in idiopathic hemochromatosis. *Can Med Assoc J* 1978;119:1051-56.
2. **Adams PC** Hepatocellular carcinoma associated with arteriohepatic dysplasia. *Dig Dis Sci* 1986;31:438-442.
3. **Adams PC** Historical Hepatology: Ludwig van Beethoven. *Journal of Gastroenterology and Hepatology* 1987;2:375-379.
4. **Adams PC** Intractability and its management. *Med J Aust* 1987;147:144.
5. **Adams PC**, Searle J. Neonatal hemochromatosis: A case and review of the literature. *Am J Gastro* 1988;83:422-425.
6. **Adams PC**, Powell L.W., Halliday J.W. Solid phase immunoradiometric assay for porcine serum ferritin. *Comp Biochem Physiol* 1988;89B:355-358.
7. **Adams PC**, Mack U., Powell L.W., Halliday J.W. Isolation of a porcine hepatic ferritin receptor. *Comp Biochem Physiol* 1988;90B:837-841.
8. **Adams PC**, Roberts F.C., Powell L.W., Halliday J.W. Chromatographic detergent exchange in the preparation of membrane receptor protein. *J Chromatography* 1988;427:341-344.
9. **Adams PC**, Powell L.W., Halliday J.W. Isolation of a human hepatic ferritin receptor. *Hepatology* 1988;8:719-721.
10. **Adams PC**, Reece A.S., Powell L.W., Halliday J.W. Hepatic iron stores in the control of iron absorption in a rat liver transplantation model. *Transplantation* 1989;48:19-21.
11. **Adams PC**, Canny C.L. Night blindness and vitamin A deficiency following jejunoileal bypass surgery. *Can J Gastro* 1989;3:138-140.
12. **Adams PC** Foreign training: difficult to obtain, but it can pay dividends. *Can Med Assoc J* 1989;141:982-984.
13. **Adams PC** Hepatic iron in hemochromatosis. *Dig Dis Sci* 1990;35:690-692.
14. **Adams PC**, Chau L. Hepatic ferritin uptake and hepatic iron. *Hepatology* 1990;11:805-808.

15. Eason R.J., **Adams PC**, Aston C.E., Searle J. Familial iron overload with possible autosomal dominant inheritance. *Aust NZ Med J* 1990;20:226-230.
16. Golubov J., **Adams PC** The university endoscopy unit - the standard of care ? *Can J Gastro* 1990;4:255-258.
17. **Adams PC**, Frei J.V., Bradley C., Lam D. Hepatic iron and iron absorption in hemochromatosis. *Clin Invest* 1990;13:256-259.
18. Delorme M., **Adams PC**, Grant D., Ghent C., Walker I., Wall W. Orthotopic liver transplantation for combined hemophilia A and B. *Am J Hematol* 1990;33:136-138.
19. Milosevic M., **Adams PC** Primary biliary cirrhosis and polymyositis. *J Clin Gastro* 1990;12:332-335.
20. **Adams PC**, Gregor J. Hemochromatosis and yersiniosis. *Can J Gastro* 1990;4:160-162.
21. **Adams PC**, Zhong R., Haist J, Flanagan P.R., Grant D.R. Mucosal iron in the control of iron absorption in a rat intestinal transplant model. *Gastroenterology* 1991;100:370-374.
22. **Adams PC**, Bradley C., Frei J.V. Hepatic zinc in hemochromatosis. *Clin Invest* 1991;14:16-20.
23. **Adams PC**, Kertesz A.E., Valberg L.S. Clinical presentation of hemochromatosis: a changing scene. *Am J Med* 1991;90:445-449.
24. Golubov J., Flanagan P.R., **Adams PC** Inhibition of iron absorption by omeprazole in a rat model. *Dig Dis Sci* 1991;36:405-408.
25. Lin E., **Adams PC** Biochemical liver profile in hemochromatosis: a survey of 100 patients. *J Clin Gastro* 1991;13:316-320.
26. **Adams PC**, Chau L.A., White M., Lazarovits A.I. Expression of transferrin receptors on monocytes in hemochromatosis. *Am J Hematol* 1991;37:247-252.
27. **Adams PC**, Speechley M., Kertesz A.E. Long term survival analysis in hereditary hemochromatosis. *Gastroenterology* 1991;101:368-372.
28. **Adams PC**, Ghent C.N., Grant D.R., Frei J.V., Wall W.J. Transplantation of haemochromatosis liver into donor: evidence against an inherited intrahepatic defect. *Gut* 1991;32:1082-1083.
29. **Adams PC**, Flanagan P.R., Chau L., White M., Lazarovits A. Monocyte membrane ferritin in hemochromatosis. *Clin Invest* 1991;14:402-408.
30. **Adams PC**, Chau L.A., Lin E., Muirhead N. The effect of recombinant human erythropoietin on iron absorption and hepatic iron concentration in a rat model. *Clin Invest* 1991;14:432-436.
31. **Adams PC**, Lin E., Barber K., Grant C. Enhanced biliary iron excretion with amphiphilic diethylenetriaminepentaacetic acid. *Hepatology* 1991;14:1230-1234.

32. **Adams PC**, Kertesz A.E. Human leucocyte antigen typing in siblings in hemochromatosis: a cost model. *Hepatology* 1992;15:263-268.
33. **Adams PC** Intrafamilial variation in hereditary hemochromatosis. *Dig Dis Sci* 1992;37:361-363.
34. **Adams PC**, Stenn P.G. Liver biopsy under hypnosis. *J Clin Gastro* 1992;15:122-124.
35. **Adams PC**, Chau L.A. Uptake of ferritin by isolated rat hepatocytes: effects of iron and metabolic inhibitors. *Clin Invest Med* 1993;16:15-21.
36. **Adams PC** Hepatocellular carcinoma in hereditary hemochromatosis. *Can J Gastro* 1993;7:37-41.
37. **Adams PC**, Kertesz A.E., Valberg L.S. Rate of iron reaccumulation in hereditary hemochromatosis: implications for venesection therapy. *J Clin Gastro* 1993;16:207-210.
38. **Adams PC** Malpractice claims and Canadian gastroenterology. *Can J Gastro* 1993;7:306-310.
39. **Adams PC** Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. *Am J Hematol* 1994;45:146-149.
40. **Adams PC** Hereditary hemochromatosis and red cell aplasia. *Am J Hematol* 1994;45:260-261.
41. **Adams PC**, Bradley C., Frei J.V. Hepatic iron and zinc determination following portacaval shunting for non-alcoholic cirrhosis. *Hepatology* 1994;19:101-105.
42. Bierbrier G, **Adams PC**, Feldman RD. Vascular alpha-adrenergic response is reduced in cirrhosis. *Clin Pharmacol Ther* 1994;56:668-671.
43. **Adams PC**, Ghent CN, Grant DR, Wall WJ. Employment after liver transplantation. *Hepatology* 1995;21:140-144.
44. Wall WJ, Ghent CN, Roy A, McAlister VC, Grant DR, **Adams PC**. Use of OKT3 monoclonal antibody as induction therapy for control of rejection in liver transplantation. *Dig Dis Sci* 1995;40:52-57.
45. **Adams PC**, Murray I, Bierbrier G. Distribution and career choices of trainees in Canadian gastroenterology. *Can J Gastroenterol* 1995;9:101-103.
46. **Adams PC**, Gregor J, Kertesz AE, Valberg LS. Blood donor screening for hemochromatosis: decision analysis based on a 30 year database. *Gastroenterology* 1995;109:177-188.
47. Oliver M, Scully L, Guiraudon C, **Adams PC**. Non-HLA linked hemochromatosis in a Chinese woman. *Dig Dis Sci* 1995;40:1589-1591.
48. Flanagan PR, Hajdu A, **Adams PC**. Iron-responsive element binding protein in hemochromatosis liver and intestine. *Hepatology* 1995;22:828-832.
49. **Adams PC**, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost effectiveness. *Hepatology* 1995;22:1720-1727.

50. Probst L, Hoffman E, Cherian G, Yang J, Feagan B, **Adams PC**, Nichols B. Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia. *Cornea* 1996;15:94-98.
51. **Adams PC**, Speechley M. The effect of arthritis on quality of life in hemochromatosis. *J Rheum* 1996;23:707-710.
52. **Adams PC**, Agnew S. Alcoholism and hereditary hemochromatosis revisited: prevalence and clinical consequences amongst homozygous siblings. *Hepatology* 1996;23:724-727.
53. **Adams PC**, Valberg LS. Evolving expression of hereditary hemochromatosis. *Sem Liv Dis* 1996;16:47-54.
54. **Adams PC**, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms and age in 410 hemochromatosis patients. *Hepatology* 1997;25:162-166.
55. Hramiak I, Finegood D, **Adams PC**. Factors affecting glucose tolerance in hereditary hemochromatosis. *Clin Invest Med* 1997;20:110-118.
56. Assy N, **Adams PC**. Predictive value of the family history in the diagnosis of hereditary hemochromatosis. *Dig Dis Sci* 1997;42:1312-1315.
57. **Moirand R, Adams PC (co-first authors)** , Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared to men. *Ann Int Med* 1997;127:105-110.
58. Boucher E, Bourienne A, **Adams PC** , Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution during therapy for chronic hepatitis C. *Gut* 1997;41:115-120.
59. **Adams PC**, Campion ML, Gandon G, Legall JY, David V, Jouanolle AM. Clinical and genetic family studies in hemochromatosis: microsatellite and *HFE* studies in five atypical families. *Hepatology* 1997;26:986-991.
60. **Adams PC**, Bradley C, Henderson AR. Evaluation of the hepatic iron index as a diagnostic criterion in genetic hemochromatosis. *J Lab Clin Med* 1997;130:509-514.
61. **Adams PC**, Chakrabarti S. Genotypic /phenotypic correlation in genetic hemochromatosis: evolution of diagnostic criteria. *Gastroenterology* 1998;114:319-323.
62. **Adams PC**. Implications of genotyping of spouses to limit investigation in children in genetic hemochromatosis. *Clinical Genetics* 1998;53:176-178.
63. **Adams PC**. Factors affecting rate of iron mobilization during venesection therapy for hereditary hemochromatosis. *Am J Hematology* 1998;58:16-19.
64. Levstik M, **Adams PC**. Eligibility and exclusion of hemochromatosis patients as voluntary blood donors. *Can J Gastro* 1998;12:61-63.
65. Burke W, Thomson E, Khoury M, McDonnell S, Press N, **Adams PC**, Barton J, Beutler E, Brittenham G, Buchanan A, Clayton E, Cogswell M, Meslin E, Motulsky A, Powell LW, Sigal E, Wilfond B, Collins F. Hemochromatosis: Gene discovery and its implications for population based screening. *JAMA* 1998;280:172-178.

66. **Adams PC.** Hemochromatosis: clinical implications of genetic testing. *Can Med Assoc J* 1998;159:156-158.
67. Guyader D, Moirand R, Jacquelinet C, Turlin B, Mendler M, Chaperon J, David V, Brissot P, **Adams PC**, Deugnier Y. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis. *Gastroenterology* 1998;115:929-936.
68. Barton JC, McDonnell S, **Adams PC**, Brissot P, Powell LW, Edwards CQ, Cook JD, Kowdley K. Management of hereditary hemochromatosis: recommendations of a CDC management working group. *Ann Int Med* 1998;129:925-931.
69. Bacon B, Powell L, **Adams PC**, Kresina T, Hoofnagle J. Molecular medicine and hemochromatosis: at the crossroads. *Gastroenterology* 1999;116:193-207.
70. Jeffrey G, Basclain K, Hajek J, Chakrabarti S, **Adams PC**. Alternate splicing produces a soluble form of the hereditary hemochromatosis protein *HFE*. *Blood Cells, Molecules and Diseases* 1999;28:61-67.
71. Kumar N, Wall WJ, Grant D, Bloch M, Ghent C, **Adams PC**, Marotta P. Liver retransplantation. *Transplantation Proceedings* 1999;31:541-542.
72. Adams P.C. Population screening for hemochromatosis. *Hepatology* 1999;29:1324-1327.
73. **Adams PC**, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. *Am J Gastroenterology* 1999;94:1593-1600.
74. McDonnell S, Preston B, Jewell S, Barton J, Edwards C, **Adams PC**, Yip R. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. *Am J Medicine* 1999;106:619-625.
75. McDonnell S, Grindon A, Preston B, Barton J, Edwards C, **Adams PC**. A survey of phlebotomy among persons with hemochromatosis. *Transfusion* 1999;39:651-656.
76. Jeffrey G, Chakrabarti S, Hegele RA, **Adams PC**. Polymorphism in intron 4 of *HFE* may cause overestimation of C282Y homozygote prevalence in haemochromatosis. *Nature Genetics* 1999;22:325-326.
77. Alanen K, Chakrabarti S, Jeffrey G, Rawlins J, Howson W, **Adams PC**. Prevalence of C282Y mutation of the hemochromatosis gene (*HFE*) in end stage liver disease: a study of liver transplant recipients and donors. *Hepatology* 1999;30:665-669.
78. **Adams PC**, Alanen K, Preshaw R, Chakrabarti S, Jeffrey G, Howson W, Grant D. Transplantation of hemochromatosis liver and intestine into a normal recipient. *Gut* 1999;45:783.
79. Arya N, Chakrabarti S, Hegele R, **Adams PC**. *HFE* S65C variant is not associated with an increased transferrin saturation in voluntary blood donors. *Blood Cells, Molecules and Diseases* 1999;25:354-357.
80. **Adams PC**, Kertesz AE, McLaren C, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron binding capacity, transferrin saturation and C282Y genotyping. *Hepatology* 2000;31:1160-1164.

81. K McLaughlin, S Wajstaub, P Marotta, **PC Adams**, D Grant, W Wall, A Jevnikar, K Rizkalla. Increased Risk of Post-Transplant Lymphoproliferative Disease in Recipients of Liver Transplants with Hepatitis C. *Liver Transplantation* 2000;6:570-574.
82. Collier J, **Adams PC**, Feinman V, Ghent C, Witt-Sullivan H, Minuk G, Kraiden M, Heathcote J. Long term follow up of patients with chronic hepatitis C treated with alpha interferon. *Can J Gastro* 2000;14:77B-80B.
83. **Adams PC**, V Bhayana. Unsaturated iron binding capacity: a screening test for hemochromatosis ? *Clinical Chemistry* 2000;46:1870.
84. Perrillo R, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, **Adams P**, Dickson R, Anscuetz G, Bell S, Condreay L, Brown N. A multi-center United States – Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. *Hepatology* 2001;33:424-432.
85. **Adams PC**. Is there a threshold of hepatic iron concentration for the development of cirrhosis in C282Y hemochromatosis ? *Am J Gastro* 2001;96:567-569.
86. Power TE, **Adams PC**. Psychosocial impact of C282Y testing for hemochromatosis in screened and referred patients. *Genetic Testing* 2001;5:107-110.
87. **Adams PC**, Walker AP, Acton RT. A primer for predicting risk in *HFE*-related hemochromatosis. *Genetic Testing* 2001;5:311-316.
88. McGrath J, Deugnier Y, Moirand R, Jouanolle AM, Chakrabarti S, **Adams PC**. A nomogram to predict C282Y hemochromatosis. *J Lab Clin Med* 2002;140:6-8.
89. Wojcik J, Speechley M, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y for hemochromatosis. *Can J Gastroenterology* 2002;16:297-302. (Awarded the ABR Thomson-N Williams Award 2003 for outstanding contribution to the Can J Gastroenterology).
90. Harrison H, **Adams PC**. Hemochromatosis: common genes, uncommon disease? *Can J Family Physician* 2002;48:1326-1333.
91. Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF, Pouchard M, Lafraise B, Brigand A, Caserio-Schoenemann C, **Adams PC**, LeGall JY, David V. Gender-specific phenotypic expression and screening strategies in C282Y-linked hemochromatosis. A study of 9396 French people. *Br J Haematology* 2002;118:1170-1178.
92. Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, **Adams PC**. Non-invasive prediction of cirrhosis in C282Y linked hemochromatosis. *Hepatology* 2002;36:673-678.
93. McLaren CE, Barton JC, **Adams PC**, Harris EL, Acton RT, Press N, Reboussin DM, McLaren GD, Sholinsky P, Walker AP, Gordeuk VR, Leiendecker-Foster C, Dawkins FW, Eckfeldt JH, Mellen BG, Speechley M, Thomson E, for the Hemochromatosis and Iron Overload Study Research Investigators. Hemochromatosis and Iron Overload Screening (HEIRS) Study Design for an Evaluation of 100,000 Primary Care-Based Adults. *Am J Med Sci* 2003;325:53-62.
94. Yamashita C, **Adams PC**. Natural history of the C282Y homozygote of the hemochromatosis gene (*HFE*) with a normal serum ferritin. *Clin Gastroenterology and Hepatology* 2003;1:388-391.

95. **Adams PC**, Barbin Y, Khan Z, Chakrabarti S. Ferroportin expression in hemochromatosis liver. *Blood Cell Mol Dis* 2003;31:256-261.
96. Power T, **Adams PC**. Hemochromatosis patients as voluntary blood donors. *Can J Gastro* 2004;18:393-396.
97. Khan Z, Barbain Y, Cukiernick M, **Adams PC**, Chakrabarti S. Heme Oxygenase-mediated Iron Accumulation in the liver. *Can J Physiol Pharm* 2004;82:448-456.
98. **Adams PC**, Arthur MJ, Boyer TD, DeLeve LD, DiBisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. *Hepatology* 2004;39: 1204-1212.
99. Shin J, Teitel J, Swain M, Bain V, **Adams PC**, Croitoru K, Peltekian K, Schweiger F, Simons M, Healthcote J. A Canadian multi-center retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: Is it safe and useful? *Am J Hematology* 2005;78:85-93.
100. Sham TK, Kim P, Ngo H, Chakrabarti S, **Adams PC**. An X-ray microspectroscopy study of hemochromatosis liver and diabetic mice kidney tissues: preliminary observations. *Physica Scripta* 2005;T115:1047-1049.
101. **Adams PC**, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. *N Eng J Med* 2005;352:1769-1778.
102. Wong K, Barbin Y, Chakrabarti S, **Adams PC**. A point mutation in the Iron-Responsive Element of the L-Ferritin in a family with hereditary hyperferritinemia cataract syndrome. *Can J Gastro* 2005;19:253-255.
103. Tan P, Marotta P, Ghent C, **Adams PC**. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. *Liver International* 2005;25:728-733.
104. **Adams PC**, Reboussin DM, Eckfeldt JH, Moses GC, Leiendecker-Foster C, McLaren CE, McLaren GD, Dawkins FW, Kasvosve I, Acton RT, Barton JC, Zaccaro D, Harris EL, Press R, Chang H. A comparison of the unsaturated iron binding capacity to transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. *Clinical Chemistry* 2005;51:1048-1052.
105. Lazarescu A, Snively B, **Adams PC**. Phenotypic variation in C282Y homozygotes of the hemochromatosis gene (*HFE*). *Clin Gastro Hep* 2005;3:1043-1046.
106. Barton J, Acton R, Dawkins F, **Adams P**, Lovato L, Leiendecker-Foster C, McLaren C, Reboussin D, Speechley M, Gordeuk V, McLaren G, Sholinsky P, Harris E. Initial screening transferrin saturation values, serum ferritin concentrations, and *HFE* genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. *Genetic Testing* 2005;9:231-241.
107. Khan Z, Farhangkhoe H, Barbin Y, **Adams PC**, Chakarbarti S. Glucose-induced regulation of novel iron transporters in vascular endothelial cell dysfunction. *Free Radical Research* 2005;39:1203-1210.

108. Tucker D, Acton RT, Press N, Ruggiero A, Reiss JA, Walker AP, Wenzel L, Harrison H, Fadojutimi-Akinsiku M, Harrison H, **Adams PC**, Crabb JA, Anderson R, Thomson E. Predictors of Belief that Genetic Test Information on Hemochromatosis Should be Shared with Family Members. *Genetic Testing* 2006;10:50-59.
109. Beaton M, **Adams PC**. Prognostic Factors and Survival in Patients with Hereditary Hemochromatosis and Cirrhosis. *Can J Gastro* 2006;20:257-260.
110. Barton J, Acton R, Lovato L, Speechley M, McLaren C, Harris E, Reboussin D, **Adams PC**, Dawkins F, Gordeuk V, Walker A. Initial screening transferrin saturation values, serum ferritin concentrations and HFE genotypes in Native Americans and Whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Clinical Genetics* 2006;69:48-57.
111. Wong K, **Adams PC**. The diversity of liver diseases associated with an elevated serum ferritin. *Can J Gastroenterology* 2006;20:467-470. – **Winner of the Thomson-Williams Award 2006 for best paper in the Can J Gastroenterology.**
112. **Adams PC**. Hemochromatosis case definition – out of focus ? *Nature – Clinical Gastroenterology and Hepatology* 2006;3:178-179.
113. **Adams PC**, Passmore L, Chakrabarti S, Reboussin D, Acton R, Barton J, McLaren G, Eckfeldt J, Dawkins F, Gordeuk V, Harris E, Leiendecker-Foster C, Gossman E, Sholinsky P. Liver diseases in participants in the Hemochromatosis and Iron Overload Screening Study. *Clin Gastro Hepatology* 2006;4:918-923.
114. Chande N, Laidlaw M, **Adams PC**, Marotta P. Yo Jyo Hen Shi (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. *Dig Dis Sci* 2006;51:183-1189.
115. Acton RT, Barton JC, Snively BM, McLaren CE, **Adams PC**, Harris EL, Speechley MR, McLaren GD, Dawkins FD, Leiendecker-Foster C, MS, Holup JL, Balasubramanyam A. Geographic and Racial/Ethnic Differences in *HFE* Mutation Frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Ethnicity and Disease* 2006;16:815-821.
116. McLaren C, Kuo-Tung L, McLaren G, Gordeuk V, Snively B, Reboussin D, Barton J, Acton R, Dawkins F, Harris E, Eckfeldt J, Moses G, **Adams PC**. Mixture models of serum biochemical measures in screening for hemochromatosis and iron overload. *Translational Medicine* 2006;148:196-206.
117. Acton R, Barton JC, Passmore L, **Adams PC**, Speechley M, Dawkins F, Sholinsky P, Reboussin D, McLaren G, Harris E, Bent T, Vogt T, Castro O. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes mellitus in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Diabetes Care* 2006;29:2084-2089.
118. Anderson R, Wenzel L, Walker A, Ruggiero A, Acton R, Hall M, Tucker D, Thompson E, Harrison B, Howe E, Holup J, Leiendecker-Foster C, Power T, **Adams PC**. Impact of Hemochromatosis Screening In Patients with Indeterminate Results: The HEIRS Study. *Genetics in Medicine* 2006;8:681-687.
119. Dawkins F, Gordeuk, V, Barton J, Acton R, McLaren G, Leiendecker-Foster C, McLaren C, **Adams P**, Speechley M, Harris E, Snively B, Lovato L, Jackson S, Thomson E.

- African Americans at risk for increased iron stores or liver disease. *Am J Med* 2007;120:734,.
120. Chatterjee A, Swain MG, Lee SS, Bain VG, Peltekian K, Croitoru K, **Adams PC**, Kaita K, Teitel J, J Heathcote. Induction versus Non-Induction Antiviral Therapy for Chronic HCV in Patients with Congenital Coagulation Disorders; a multicentre Canadian trial. *Can J Gastro* 2007;21:91-95.
 121. Beaton M, **Adams PC**. The myths and realities of hemochromatosis. *Can J Gastro* 2007 21:101-104.
 122. Nazareno J, Driman D, **Adams PC**. Is Helicobacter Pylori Being Treated Appropriately? A Study of Inpatients and Outpatients in a Tertiary Care Centre. *Can J Gastro* 2007;21:285-288.
 123. Hall M, Barton JC, **Adams PC**, McLaren CE, Reiss J, Castro O, Ruggiero A, Acton R, Power T, Bent T. Genetic screening for iron overload: No evidence of discrimination at one year. *J Fam Practice* 2007;56:829-833.
 124. Steiner M, Leiendecker-Foster C, McLaren G, Snively B, McLaren C, **Adams PC**, Eckfeldt J. *HFE* Gene Splice Site Mutation IVS5 + 1 G/A in North American Vietnamese With and Without Phenotypic Evidence of Iron Overload. *Translational Medicine* 2007;149:92-95.
 125. Power T, **Adams PC**, Barton JC, Acton RT, Howe E, Palla S, Walker A, Anderson R, Harrison B, Thomson E. Psychosocial Impact of Genetic Testing for Hemochromatosis (*HFE* mutation analysis) in the HEIRS Study: A comparison of participants recruited in Canada and in the United States. *Genetics in Medicine* 2007;11:55-64.
 126. Gagne G, Reinharz D, Laflamme N, **Adams PC**, Rousseau F. Hereditary hemochromatosis : effect of mutation penetrance and prevalence on cost-effectiveness of screening modalities. *Clinical Genetics* 2007;71:46-58.
 127. Harris E, McLaren CE, Reboussin D, Gordeuk V, Barton JC, Acton R, McLaren G, Vogt T, Snively B, Leiendecker-Foster C, Holup J, Passmore L, Eckfeldt J, Lin E, **Adams PC**. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. *Arch Int Med* 2007;167:722-726.
 128. Rivers C, Barton JC, Gordeuk V, Acton R, Speechley M, Snively B , Leiendecker-Foster C, Press R, **Adams PC**, McLaren GD, Dawkins F, McLaren C , Reboussin R. Association of Ferroportin Q248H Polymorphism with Elevated Levels of Serum Ferritin in HEIRS Study African American Participants. *Blood Cell Mol Dis* 2007;38:247-252.
 129. Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, **Adams PC**, McLaren G, Eckfeldt J, McLaren CE, Reboussin D, Gordeuk V, Speechley M, Reiss J, Press R , Dawkins F. Prevalence and characteristics of HFE C282Y homozygotes and persons with self-reported hemochromatosis or iron overload at HEIRS Study initial screening of 7,343 participants who were ages 25-29 years. *Genetic Testing* 2007;11:269-275.
 130. Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, **Adams PC**, McLaren G, Eckfeldt J, McLaren CE, Reboussin D, Gordeuk V, Speechley M, Reiss J, Press R , Dawkins F. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening. *Am J Hematol.* 2008;83:126-132..
 131. **Adams PC**, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren G, Dawkins F, Gordeuk V, Lovato L, Eckfeldt J. Biological variability

- of transferrin saturation and unsaturated iron binding capacity. *Am J Med* 2007;120:999.e1.-e7.
132. McLaren C, Barton J, Gordeuk V, Wu L, **Adams PC**, Reboussin DM, Speechley M, Chang H, Acton RT, Harris EL, Castro O. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white *HFE* C282Y homozygotes in the hemochromatosis and iron overload. *Am J Hematology* 2007;82:898-905.
 133. Acton RT, Snively BM, Barton JC, McLaren CE, **Adams PC**, Rich SS, Eckfeldt JH, Press RD, Sholinsky P, Leiendecker-Foster C, McLaren GD, Speechley MR, Harris EL, Dawkins FW, Gordeuk VR. A genome-wide search for hemochromatosis susceptibility loci. *Clinical Genetics* 2007;71:518-529.
 134. Assy N, **Adams PC**, Myers P, Simon V, Minuk G, Wall W, Ghent C. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. *Transplantation* 2007;83:1571-1576.
 135. **Adams PC**, Reboussin DM, Barton JC, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, Gordeuk V, Dawkins F, Eckfeldt JH. Serial serum ferritin measurements in untreated *HFE* C282Y homozygotes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Int J Lab Hematol* 2008;30:300-305.
 136. Walker AP, Tucker DC, Hall MA, Lohman K, Harrison H, Harrison B, Reiss J, Acton RT, **Adams PC**, Sharmin D, Holup J, Thomson E, Ellis SD, McLaren CE. Results communication and patient education after screening for possible hemochromatosis and iron overload: Experience from the HEIRS Study of a large ethnically and linguistically diverse group. *Genetics in Medicine* 2007;9:778-791.
 137. McLaren C, Gordeuk V, Chen W, Barton JC, Acton RT, Speechley M, Castro O, **Adams PC**, Snively BM, Harris EL, Reboussin DM, McLachlan GJ, Bean R. Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Translational Research* 2008;151:97-109.
 138. Gordeuk V, Reboussin D, McLaren C, Barton J, Acton R, McLaren G, Harris E, Reiss J, **Adams PC**, Speechley M, Phatak P, Sholinsky P, Eckfeldt J, Chen W, Passmore L, Dawkins F. Serum ferritin concentrations and body iron stores in a multi-center, multi-ethnic primary care population. *Am J Hematology* 2008;83:618-626.
 139. Acton RT, Barton JC, Passmore L, **Adams PC**, McLaren G, Leiendecker-Foster C, Speechley M, Harris EL, Castro O, Reiss JA, Snively B, Harrison BW, McLaren C. Accuracy of family history of hemochromatosis or iron overload: The Hemochromatosis and Iron Overload Screening Study. *Clin Gastro Hep* 2008;6:934-938.
 140. Beaton M, **Adams PC**. Prevalence of silent liver fibrosis in C282Y homozygotes with normal transaminases. *Clin Gastro Hep* 2008;6:713-714.
 141. **Adams PC**, McAlister V, Chakrabarti S, Levstik M, Marotta P. Is serum hepcidin causative in hemochromatosis? Novel analysis from a liver transplant with a hemochromatosis liver. *Can J Gastro* 2008;22:851-853.
 142. Harrison H, Harrison B, Walker A, Lohman K, Ellis S, Hall M, Reiss J, **Adams PC**, Holup J, Acton R, Bent T, Rivers C, Fadojutmi-Akinsiku M. Satisfaction with Results Notification

- and Understanding of Mailed Results in Unaffected Participants of the HEIRS Study. *Genetic Testing* 2008;12:491-500.
143. Barton JC, Leiendecker-Foster C, Reboussin DM, **Adams PC**, Acton RT, Eckfeldt JH. Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: The HEIRS Study. *Thyroid* 2008;18:831-838.
 144. Beaton M, Taylor B, Driman D, Ainsworth P, **Adams PC**. Colonic interposition in a woman with attenuated familial adenomatous polyposis: Does the location of the colon affect polyp formation? *Can J Gastro* 2008;7:634-636.
 145. Pankow JS, Boerwinkle E, **Adams PC**, Guallar E, Leiendecker-Foster C, Rogowski J, Eckfeldt JH. *HFE* C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. *Translational Research* 2008;152:3-10.
 146. McLaren GD, McLaren CE, **Adams PC**, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH. Clinical manifestations of hemochromatosis in *HFE* homozygotes identified by screening. *Can J Gastro* 2008;22:923-930.
 147. **Adams PC**, Pankow J, Barton JC, Acton RT, Leiendecker-Foster C, McLaren GD, Speechley M, Eckfeldt J. *HFE* C282Y homozygosity is associated with lower total and LDL cholesterol: the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Circulation: Cardiovascular Genetics* 2009;2:34-37.
 148. **Adams PC**. The lost years: The effects of cirrhosis on the history of jazz. *Can J Gastro* 2009;23:405-406.
 149. Sarin N, Monga N, **Adams PC**. Time to Endoscopy and Outcomes in Upper Gastrointestinal Bleeding. *Can J Gastro* 2009;23:489-493
 150. Roth L, **Adams PC**. Variation for physician reimbursement for endoscopy across Canada. *Can J Gastro* 2009;23:503-505.
 151. Barton JC, Leiendecker-Foster C, Reboussin DM, **Adams PC**, Acton RT, Eckfeldt JH. Relationships of serum free thyroxine and erythrocyte measures in euthyroid *HFE* C282Y homozygotes and control subjects in the HEIRS Study. *Int J Lab Haematology* 2008;30:300-305.
 152. **Adams PC**, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively B, Vogt T, Sholinsky P, Dawkins FW, Gordeuk VR, Eckfeldt JH. Screening for iron overload: Lessons from the HEIRS Study. *Can J Gastro* 2009;23:769-772.
 153. Koutsogiannis D, Summers K, George B, **Adams P**, Marotta P, Chakrabarti S. Identification of serum biomarkers in end stage liver disease. *The Open Biomarkers Journal* 2009;2:14-19.
 154. Ko JY, Sham TK, Chakrabarti S, **Adams PC**. Synchrotron X-ray microscopy and spectroscopy analysis of iron in hemochromatosis liver and intestines. *Journal of Physics* 2009;doi:10.1088/1742-6596/190/1/012207.

155. McLaren CE, Barton J, Eckfeldt J, McLaren G, Acton R, **Adams PC**, Henkin L, Gordeuk V, Vulpe C, Harris E, Harrison B, Reiss J, Snively B. Heritability of serum iron measures in the Hemochromatosis and Iron Overload Screening (HEIRS) Family Study. *Am J Hematol* 2010;85:101-105.
156. **Adams PC**, Barton JC. How I Treat Hemochromatosis. *Blood* 2010;116:317-325.
157. P Phatak, P Brissot, M Wurster, **PC Adams**, H Bonkovsky, J Gross, P Malfertheiner, G McLaren, C Niederau, A Piperno, L Powell, M Russo, U Stoelzel, W Stremmel, L Griffel, N Lynch, Y Zhang, A Pietrangelo. A phase I/II, dose-escalation trial of deferasirox for the treatment of iron overload in *HFE*-related hereditary hemochromatosis *Hepatology* 2010;52:1671-1679.
158. Bacon BR, **Adams PC**, Kowdley K, Powell LW, Tavill AS. Diagnosis and Management of Hemochromatosis: AASLD Practice Guidelines. *Hepatology* 2011;54:328-343.
159. Symonette C, **Adams PC**. Do all hemochromatosis patients have the same origin? *Can J Gastro* 2011;25:324-326.
160. Christine McLaren, Chad Garner, Clare Constantine, Stela McLachlan, Chris Vulpe, Beverly Snively, Victor Gordeuk, Deborah Nickerson, James Cook, Catherine Leiendecker-Foster, Kenneth Beckman, John Eckfeldt, Lisa Barcellos, Joseph Murray, **Paul Adams**, Ronald Acton, Anthony Killeen, and Gordon McLaren. Genome-wide association study identifies genetic loci associated with iron deficiency. *PLOS One* 2011;6:e17390.
161. Gordeuk V, Lovato L, Vitolins M, McLaren G, Acton R, Barton J, McLaren C, Harris E, Speechley M, Eckfeldt J, Diaz S, Sholinsky P, **Adams PC**. Relationship between dietary iron intake and serum ferritin concentration in *HFE* homozygotes. *Can J Gastro* 2012;26:345-349.
162. **Adams PC**, Beaton M. Transferrin saturation as a predictor of hepatic iron overload. *Liver International* 2011;31:272-273.
163. **Adams PC**, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. *J Hepatology* 2011;55:453-458.
164. Speechley M, Alter D, Harrison H, Guo H, **Adams PC**. Effect of ambiguous hemochromatosis gene test results on physician utilization. *Medical Care* 2012;50:394-398.
165. Chandok N, Speechley M, Ainsworth P, Chakrabarti S, **Adams PC**. The impact of population based screening studies on hemochromatosis screening practices. *Dig Dis Sci* 2012;57:1420-1422.
166. McLaren CE, McLachlan S, Garner CP, Vulpe CD, Gordeuk VR, Eckfeldt JH, **Adams PC**, Acton RT, Murray JA, Leiendecker-Foster C, Snively BM, Barcellos LF, Cook JD, McLaren, GD. Associations between Single Nucleotide Polymorphisms in Iron-related Genes and Iron Status in Multiethnic Populations. *PLOS One* 2012;7(6):e38339. Epub 2012 Jun 22.2012;
167. **Adams PC**, Speechley M, Barton J, McLaren C, McLaren G, Eckfeldt J. Probability of C282Y-linked hemochromatosis decreases as liver transaminase activities increase in participants with hyperferritinemia in the HEIRS study. *Hepatology* 2012;55:1722-1726.

168. **Adams PC.** Evaluation of cirrhosis with an elevated ferritin. *Clin Gastro Hep* 2012;10:368-370.
169. Barton JC, Barton JC, Acton RT, So J, Chan S, **Adams PC.** Increased mortality risk due to iron overload associated with serum ferritin >1000 µg/L at diagnosis in 422 treated hemochromatosis probands with *HFE* C282Y homozygosity in two referral practices. *Clin Gastro Hep* 2012;10:412-416.
170. Wells M, Chande N, **Adams PC,** Beaton M, Levstik M, Boyce E, Mrkobrada M. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. *Alimentary Pharm Ther* 2012;35:1267-1278.
171. Croome KP, McAlister V, Quan D, **Adams PC,** Al-Basheer M, Marotta P, Wall W, Hernandez-Alejandro R. Endoscopy management of biliary complications following liver transplantation from donation after cardiac death donors. *Can J Gastro* 2012;26:607-610.
172. Ludvigsson J, Murray JA, **Adams PC,** Elmberg M. Does hemochromatosis predispose to celiac disease ? *Scand J Gastro* 2013;48:176-182.
173. Beaton M, Chakrabarti S, Levstik M, Speechley M, Marotta P, **Adams PC.** Phase II Clinical Trial of Phlebotomy Therapy for non-alcoholic liver disease. *Alimentary Pharmacology and Therapeutics* 2013;37:720-729.
174. Sey M, Gregor J, Adams PC, Khanna N, Vinden C, Driman D, Chande N. Wait times for diagnostic colonoscopy among outpatients with colorectal cancer: A comparison with Canadian Association of Gastroenterology targets. *Can J Gastro* 2012;26:894-896.
175. Murray JA, McLachlan S, **Adams PC,** Eckfeldt JH, Garner CP, Vulpe CD, Gordeuk VR, Branter T, Leiendecker-Foster C, Killeen AA, Acton RT, Barcellos LF, Nickerson DA, Beckman KB, McLaren GD, McLaren CE. Celiac disease: association with iron deficiency in Caucasians but not in non-Caucasians. *Clin Gastroenterol Hepatol* 2013;11:808-814.
176. **Adams PC,** McLaren CE, Speechley M, McLaren GD, Barton JC, Eckfeldt JH. *HFE* mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening (HEIRS) Study with serum ferritin < 1000 µg/L. *Can J Gastro* 2013;27:390-392.
177. Barton JC, **Adams PC,** Acton RT, Speechley M, McLaren CE, McLaren GD, Gordeuk V, Eckfeldt J. Proton pump inhibitors and lower serum ferritin levels in 171 *HFE* C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. *Vitamins and Minerals* 2013;112:doi:10.4172
178. Croome KP, Segal D, Hernandez-Alejandro R, **Adams PC,** Thomson A, Chandok N. Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants. *J Hepatobiliary Pancreat Sci* 2014;21:269-274.
179. Beaton M, Chakrabarti S, **Adams PC.** Inflammation is not the cause of an elevated serum ferritin in Non-Alcoholic Fatty Liver Disease. *Annals Hepatology* 2014;13:353-356.
180. Barton JC, Barton JC, **Adams PC,** Acton RT. Risk Factors for Insulin resistance, metabolic syndrome and diabetes in 248 *HFE* C282Y homozygotes identified in the HEIRS study screening. *Metabolic Diseases and Related Disorders* 2016;14:1-8.

181. **Adams PC**, Barton JC, Guo H, Alter D, Speechley M. Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study. *Ann Hep* 2015;14:348-353.
182. Lim A, Speechley M, **Adams PC**. Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation in 44,809 participants from the HEIRS study. *Can J Gastro Hep* 2014;28:505-509.
183. McLaren CE, Emond MJ, Subramaniam VN, Phatak PD, Barton JC, **Adams PC**, Goh JB, McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm GA, Anderson GJ, McLaren GD. Exome sequencing in *HFE* C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe Iron overload. *Hepatology* 2015;62:429-439.
184. Levstik A, Stuart A, **Adams PC**. GNPAT Variant (D519G) is not associated with an elevated serum ferritin or iron removed by phlebotomy in patients referred for C282Y-linked hemochromatosis. *Ann Hepatology* 2016;15:907-910.
185. Kumar N, Rizek P, Sadikovic B, **Adams PC**, Jog M. Movement Disorders associated with Hemochromatosis. *Can J Neurosciences* 2016;43:801-808.
186. Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, **Adams PC**, Kim RB, Tirona RG. A Fibroblast Growth Factor 21 - Pregnane X Receptor Pathway Downregulates Hepatic Cytochrome P450 3A4 in Nonalcoholic Fatty Liver Disease. *Mol Pharm* 2016;90:437-446..
187. Lanktree M, Sadikovic B, Waye J, Levstik A, Lanktree B, Yudin J, Crowther M, Pare G, **Adams PC**. Clinical evaluation of a hemochromatosis next-generation sequencing gene panel. *Eur J Haematol* 2016;98:228-234.
188. Barton JC, Chen WP, Emond M, Phatak P, Subramaniam N, **Adams PC**, Gurrin L, Anderson G, Ramm G, Powell LW, Allen K, Phillips J, Parker C, McLaren GD, McLaren CE. GNPAT p.D519G is independently associated with markedly increased iron stores in *HFE* p. C282Y homozygotes. *Blood Cell Mol Dis* 2017;63:15-20.
189. Barton J, **Adams PC**, Acton R, Barton JC. Undiagnosed diabetes and impaired fasting glucose in *HFE* C282Y homozygotes and *HFE* wild-type controls in the HEIRS Study. *BMJ Open Diabetes Research and Care* 2016; doi.org/10.1136.bmjdr-2016-000278.
190. Barton JC, Barton JC, **Adams PC**. Clinical and laboratory associations with persistent hyperferritinemia in 373 black HEIRS Study participants. *Ann Hepatology* 2017;16:802-811.
191. Sadikovic B, Hegele R, Aref-Eshghi E, Knoll J, Lin H, Kerkhof J, Stuart A, **Adams PC**, Rodenhiser D, McRobbie S, Reilly J, Rupar T, Cigana Schenkel L, Ainsworth P. Clinical Validation of Copy Number Variant Detection from Targeted Next Generation Sequencing Panels. *J Molecular Diagnostics* 2017Aug 14. pii: S1525-1578(17)30207-6. doi: 10.1016/j.jmoldx.2017.07.004. [Epub ahead of print]
192. **Adams PC**, Xenocostas A, Howlett C, Chakrabarti S. Gender-specific cellular identification post liver transplantation in hemochromatosis with aplastic anemia and hepatocellular carcinoma. *Hepatology Communications* 2017 (resubmitted).

Review Articles

193. **Adams PC** Recent Advances in Hepatology. Fellowship Affairs of the Royal College of Physicians of Australia, December 1987;24-26.
194. **Adams PC**, Halliday J.W., Powell L.W. Early diagnosis and screening for hemochromatosis. *Advances in Internal Medicine* 1989;34:111-126.
195. **Adams PC** A quarter century of liver transplantation - learning from livers. *Can J Gastro* 1989;3:162-164.
196. **Adams PC** Hemochromatosis and Wilson's disease. *Manitoba Medicine* 1991;61:146-148.
197. **Adams PC** Uncovering the symptoms of Hemochromatosis. *Can J Diag* 1993;10:127-135.
198. **Adams PC** Hemochromatosis Update. *Liver Update, American Liver Foundation*,1993;7:1-
199. Wall WJ, **Adams PC**. Liver transplantation for fulminant liver failure: North American experience. *Liver Transplantation and Surgery* 1995;1:178-182.
200. CASL Hepatitis Consensus Group. Treatment of chronic viral hepatitis with alpha-interferon: a consensus conference report. *Can J Gastroenterol* 1994;8:179 -184.
201. **Adams PC**. Hemochromatosis - iron overload. *Medicine North America* 1996;19:43-48.
202. CASL Hepatitis Consensus Group. Management of viral hepatitis: clinical and public health perspectives. *Can J Gastroenterol* 1997;11:407-416.
203. **Adams PC**. Hepatitis and the physician. *Hepatology Update* 1997. *Can J Gastro* 1998;12:17-20.
204. **Adams PC**. Diagnosis of hemochromatosis: role of genetic testing and liver biopsy. *Current Gastroenterology Reports* 1999;1:27-29.
205. Jeffrey G, **Adams PC**. Pitfalls in the diagnosis of genetic hemochromatosis. *Genetic Testing* 2000;4:143-146.
206. **Adams PC**. Hemochromatosis: Genetic diagnosis and management. *Gastroenterology Rounds, University of Alberta* June/July 2000;4, issue 6.
207. **Adams PC**, Brissot P, Pietrangelo A, Powell LW. EASL International Consensus Conference on Haemochromatosis. *J Hepatology* 2000;33:485-505.
208. **Adams PC**. Non-expressing C282Y homozygotes for hemochromatosis: minority or majority of cases ? *Molecular Genetics and Metabolism* 2000;71:81-86.
209. **Adams PC**. Hemochromatosis: Clinical Implications. *Medscape*, January 2002 (<http://www.medscape.com>).
210. **Adams PC**. Screening for hemochromatosis – should we be doing the last test first ? *BCMA* 2002;44:83-85.

211. **Adams PC.** Population screening for hemochromatosis – Are we finding people with a disease or a biochemical curiosity ? *Seminars in Gastrointestinal Disease* 2002;13:89-94.
212. Harrison H, **Adams PC.** Hemochromatosis: how many cases are we missing? *Can J CME* 2002;14:103-110.
213. **Adams PC,** Harrison H. Hemochromatosis Screening: Strategies to prevent the complications of this common genetic condition. *Parkhurst Exchange* 2003;11:56-61.
214. **Adams PC.** The modern diagnosis and management of hemochromatosis. *Aliment Pharmacol Ther* 2006;23:1681-1691.
215. Tavill AS, **Adams PC.** A diagnostic approach to hemochromatosis. *Can J Gastro* 2006 20:535-540.
216. **Adams PC,** Barton JC. Haemochromatosis. *Lancet* 2007;370:1855-60.
217. Harrison H, **Adams PC.** Hemochromatosis. *Parkhurst Exchange* 2007;15:84-85.
218. Beaton M, **Adams PC.** Haemochromatosis. *BMJ Learning Module* 2009 <http://learning.bmj.com/learning/search-result.html?moduleId=10012540> .
219. **Adams PC.** The natural history of untreated *HFE*-related hemochromatosis. *Acta Haematologica* 2009;122:134-139.
220. Beaton M, **Adams PC.** Treatment of hyperferritinemia. *Ann Hepatology* 2012;11:294-300.
221. Cottrell J, **Adams PC.** Top ten things rheumatologists should know about detection and treatment of hemochromatosis. *Can J Rheumatology* 2015;25:26-27.

Editorials

222. **Adams PC,** Powell L.W. Porphyria cutanea tarda and HLA-linked hemochromatosis - All in the family ? *Gastroenterology* 1987;92:2033-2035.
223. **Adams PC** Hepatitis B Vaccine - Nothing lasts forever. *Journal of Gastroenterology and Hepatology* 1987;2:97-99.
224. **Adams PC,** Powell L.W. Autoimmune chronic active hepatitis - Should we be searching for an elusive (auto)antigen ? *Journal of Gastroenterology and Hepatology* 1988;3:199-203.
225. **Adams PC.** Traffic jam for the hemochromatosis mutant protein. *Hepatology* 1997;26:1684.
226. **Adams PC.** Iron overload in alcoholic and viral liver disease. *J Hepatology* 1998;28:19-20.
227. Jeffrey G, **Adams PC.** Blood from patients with hereditary hemochromatosis – a wasted resource ?. *Transfusion* 1999;39:549-550.
228. **Adams PC.** Population screening for haemochromatosis. *Gut* 2000;46:301-303.

229. **Adams PC.** Iron overload in Montpellier. *Gut* 2001;6:753-756.
230. **Adams PC.** Hemochromatosis: the irony of population screening. *Scand J Gastro* 2001;36:1009-1110.
231. **Adams PC.** Lessons from liver transplantation – flip, flop and why ? *Gut* 2003;52:318.
232. **Adams PC.** Screening for haemochromatosis – find them or forget them ? *Eur J Gastro Hep* 2004;16:857-858.
233. **Adams PC.** Screening for haemochromatosis – preventing or producing illness ? *Lancet* 2005;366:269-271.
234. **Adams PC.** The Canadian Journal of Gastroenterology 2005: the new team. *Can J Gastro* 2005;19:397.
235. Murray I, Chiba N, **Adams PC.** Ambulatory endoscopy – perspectives from the community. *Can J Gastro* 2005;19;8:471-473.
236. Crowther M, **Adams PC.** Anticoagulants and gastrointestinal bleeding. *Can J Gastroenterol* 2005;19:535-537.
237. Simpson J, **Adams PC.** A ruling supreme ? *Can J Gastro* 2005;19:597-599.
238. Richman J, **Adams PC.** Disabling disability claims in gastroenterology. *Can J Gastro* 2005;19:653-656.
239. Butcher R, **Adams PC.** Doing the 'right' thing as a gastroenterologist. *Can J Gastro* 2005;19:707-708.
240. Fenlon H, **Adams PC.** The future of virtual colonography. *Can J Gastro* 2006;20:11-13.
241. Williams R, **Adams PC.** A new code for a new relationship. *Can J Gastro* 2006;20 73-74.
242. Wong W, **Adams PC.** Sex and the scope. *Can J Gastro* 2006;20;151-152.
243. Rabeneck L, **Adams PC.** Colorectal cancer screening: opportunistic or organized ? *Can J Gastro* 2006;20:249-250.
244. Fontana R, **Adams PC.** Unintentional acetaminophen overdose on the rise; who is responsible ? *Can J Gastro* 2006;20:319-324.
245. Campbell N, **Adams PC.** Scoping out GI nurses. *Can J Gastro* 2006;20:397.
246. Day CP, **Adams PC.** A chat on fat in the liver. *Can J Gastro* 2006;20;461-462.
247. Morse J, **Adams PC.** Northern Scopes. *Can J Gastro* 2006;20:515.
248. Case S, **Adams PC.** Celiac disease – hidden and dangerous. *Can J Gastro* 2006;20:571-573.
249. **Adams PC.** Ainsworth P. A burning desire to study genetic mutations in gastroenterology. *Can J Gastro* 2006;20:629-630.

250. Bach D, **Adams PC**. In search of a technical fee for endoscopy in Ontario. *Can J Gastro* 2006;20:689-690.
251. Bhandari R, **Adams PC**. Propofol for endoscopy in Canada – a sleepy or slippery slope. *Can J Gastro* 2006;20:765-766.
252. Nelson DB, **Adams PC**. Infection control during gastrointestinal endoscopy. *Can J Gastro* 2007;21:14-15.
253. Finegood D, **Adams PC**. Tracking trends in Canadian gastroenterology research. *Can J Gastro* 2007;21:77-80.
254. Paterson W, **Adams PC**. Esophageal motility studies – the spastic truth. *Can J Gastro* 2007;21:147-148.
255. Jovey R, **Adams PC**. Coping with chronic pain in gastroenterology patients. *Can J Gastro* 2007;21:211-212.
256. Colby D, **Adams PC**. Curry and a hurry? *Can J Gastro* 2007;21:275.
257. Todd T, **Adams PC**. Liability for delays in diagnosis – waiting for trouble ? *Can J Gastro* 2007;21:351-352.
258. Bacon BR, **Adams PC**. Hepatology as a distinct specialty – Born in the USA? *Can J Gastro* 2007;21:421.
259. Czaykowski P, **Adams PC**. Therapy of colon carcinoma: an oncology perspective. *Can J Gastro* 2007, 21:483-486.
260. Carter R, **Adams PC**. Coping with complications. *Can J Gastro* 2007, 21:551-552.
261. Jacobson K, **Adams PC**. Pediatric Gastroenterology – Are you kidding ? *Can J Gastro* 2007;21:631-632.
262. Sands BE, **Adams PC**. Crohn's Disease: Advise and consent. *Can J Gastro* 2007;21;791-793.
263. Urbain JL, **Adams PC**. Positron emission tomography and gastroenterology. *Can J Gastro* 2008;22;15-16.
264. Fagan G, **Adams PC**. LiverRight: making liver health relevant for all Canadians. *Can J Gastro* 2008;22:113-114.
265. Bridges R, **Adams PC**. Building your Babylon. *Can J Gastro* 2008;22:233-235.
266. Louie T, **Adams PC**. Nature's therapy for recurrent C. Difficile colitis. *Can J Gastro* 2008 22;455-456.
267. **Adams PC**. Management of elevated serum ferritin levels. *Gastroenterology and Hepatology* 2008;4:333-334.
268. Rostom A, **Adams PC**. Does one pill per day keep the colonoscopist away ? *Can J Gastro* 2008;22:545-546.

269. Lock M, **Adams PC**. Hepatic lesion radiotherapy: a new option ? Can J Gastro 2008;22:611-613.
270. Marshall J, **Adams PC**. The irritable infection. Can J Gastro 2008;22:669-670.
271. Panaccione R, **Adams PC**. Crohn's disease: we're in it for the long haul. Can J Gastro 2008;22:803-804.
272. **Adams PC**. The cycle of fifths. Can J Gastro 2008;22:676.
273. Marshall B (Nobel Prize Laureate), **Adams PC**. Helicobacter pylori: A Nobel pursuit ? Can J Gastroenterology 2008;22:895-896.
274. Cooper C, **Adams PC**. Hepatitis treatment in the era of HAART therapy for HIC. Can J Gastro 2008;22:973-975.
275. **Adams PC**. Hemochromatosis: heading down the up elevator ? Gastroenterology 2008;135:1855-1857.
276. Ghosh S, **Adams PC**. Advances in inflammatory bowel disease: are the patients taking their medicine ? Can J Gastroenterology 2009;23:13-14.
277. Goodyear J, **Adams PC**. Allocation of GI positions in Ontario: supply or demand? Can J Gastroenterology 2009;23:82-82.
278. **Adams PC**. So you want to be an Editor? Can J Gastro 2009;23:157.
279. Anderson F, **Adams PC**. The LAIR Centre: bridging community practice and clinical research. Can J Gastro 2009;23:253-254.
280. Gish R, **Adams PC**. Therapy for hepatitis B: La Nouvelle Vague. Can J Gastro 2009;23:407-409.
281. Barkun A, **Adams PC**. Urgent endoscopy: what's the rush ? Can J Gastro 2009;23:475-476.
282. Forsmark C, **Adams PC**. Pancreatic function testing: Valuable but underused. Can J Gastroenterology 2009;23:529-530.
283. Gould M, **Adams PC**. Outpatient screening colonoscopy: Why not the standard of care? Can J Gastro 2009;23:587-589.
284. Sherman P, **Adams PC**. Re:Search for Research. Can J Gastro 2009;23:668-669.
285. Cepo J, **Adams PC**. Diet and Crohn's Disease: Facts or folly ? Can J Gastro 2009;23:747-748.
286. Wilcox CM, **Adams PC**. Are we on track for the education of future gastroenterologists ? Can J Gastro 2010;23:794-795.
287. Barton JC, **Adams PC**. Screening, diagnosis and management of *HFE*-hemochromatosis. Nature Gastroenterology and Hepatology 2010;7:482-484.
288. **Adams PC**. Chelation therapy for secondary iron overload – is the primary endpoint less iron or less fibrosis ? Gastroenterology 2011;141:1142-1143.

289. **Adams PC.** Serum ferritin levels and type 2 diabetes –Are body stores elevated ? *Nature (Endocrinology)* 2012;8:573-575.
290. **Adams PC.** Hpcidin and hemochromatosis: the message or the messenger ? *Hepatology* 2014;59:749-750.
291. **Adams PC.** H63D genotyping for hemochromatosis - Helper or hindrance ? *Can J Gastro Hep* 2014;28:179-180.
292. **Adams PC.** Genetic testing for hemochromatosis: diagnostic or confirmatory for iron overload ? *Can J Gastro Hep* 2015;29:15-16.
293. **Adams PC.** The (il)logic of iron reduction therapy for steatohepatitis. *Hepatology* 2015;62:668-669.
294. **Adams, PC.** Is DNA-based testing for hemochromatosis reliable? Expert Review of Molecular Diagnostics 2017 (<http://dx.doi.org/10.1080/14737159.2017.1283221>)
295. **Adams PC.** The irony of long term acid suppression. *Gastroenterology* 2017 (n press).

Book chapters

296. **Adams PC,** Valberg L.S. Hereditary hemochromatosis. In: *The Logic of Laboratory Medicine.* Eds. Noe D., Rock R., Williams & Wilkins, Baltimore 1994;525-534.
297. **Adams PC** Hemochromatosis, Alpha-1-anti-trypsin deficiency, Wilson's disease. In: *First Principles of Gastroenterology.* Eds. Thomson A.B.R., Shaffer E.A. 2nd Edition, University of Toronto Press, Toronto 1994: 455-457.
298. **Adams PC** Metal overload disorders. Current diagnosis and treatment in *Gastroenterology.* Eds. Grendell J, McQuaid K, Friedman S. Lange Medical Publications, 1996;539-547.
299. **Adams PC** Current therapy of hemochromatosis. In: *Conn's Current Therapy,* Ed. Rakel RE, WB Saunders, Philadelphia 1996;382-383.
300. **Adams PC** Inherited liver disease. In: *First Principles of Gastroenterology.* Eds. Thomson A.B.R., Shaffer E.A. 3rd Edition, Canadian Association of Gastroenterology, Edmonton 1997;512-514 .
301. **Adams PC.** Hemochromatosis: New insights in pathogenesis and diagnosis following the discovery of the gene. *Clinical Reviews in Laboratory Medicine.* CRC Press 1998 ;35:239-273.
302. Jeffrey G, **Adams PC.** Hemochromatosis and Wilson Disease: Diagnosis and management strategies. *Evidence-Based Gastroenterology.* Eds. JWD McDonald, A Burroughs, B Feagan. BMJ Books (London) 1999:333-345.
303. **Adams PC** Hemochromatosis and liver transplantation. *Hemochromatosis.* Eds. C.Q. Edwards, J. Barton, 1st Edition, Cambridge University Press, Cambridge 2000;355-358.
304. J Barton, S McDonnell, **Adams PC,** P Brissot, LW Powell, C Edwards, J Cook, K Kowdley. Management of hemochromatosis. *Hemochromatosis.* Eds. C.Q. Edwards, J. Barton, 1st Edition, Cambridge University Press, Cambridge 2000;329-338.

305. **Adams PC** Inherited liver disease. In: First Principles of Gastroenterology. Eds. Thomson A.B.R., Shaffer E.A. 4th Edition, Canadian Association of Gastroenterology, Edmonton 2000 554-559.
306. **Adams PC**. Molecular and Cellular Iron Transport. Hemochromatosis: diagnosis and management after the discovery of the gene. Editor, Douglas Templeton. 1st Edition, Marcel Dekker 2002; 699-724.
307. **Adams PC**. Update on hemochromatosis. Evidence-Based Gastroenterology. Eds. JWD McDonald, A Burroughs, B Feagan. BMJ Books (London) 2000 (www.evidbasedgastro.com).
308. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy, Ed. Rakel RE, WB Saunders, Philadelphia 2002;401-403.
309. **Adams PC** Iron overload disorders. Current diagnosis and treatment in Gastroenterology. Eds. Grendell J, McQuaid K, Friedman S. 2nd Edition, Lange Medical Publications;2002:616-621.
310. **Adams PC**. Hemochromatosis. Textbook of Gastroenterology, Yamada T et al. eds. Lippincott, Williams & Wilkins, 4th edition;2003:2388-2396
311. **Adams PC**. Hemochromatosis. In Clinics in Liver Diseases. Eds. Bruce Bacon. 2004;8:735-753.
312. Jeffrey G, **Adams PC**. Hemochromatosis and Wilson Disease: Diagnosis and management strategies. Evidence-Based Gastroenterology, 2nd Edition. Eds. JWD McDonald, A Burroughs, B Feagan. Blackwell (London)2004:405-414.
313. **Adams PC** Hemochromatosis. In: First Principles of Gastroenterology. Eds. Thomson A.B.R., Shaffer E.A. 5th Edition, Canadian Association of Gastroenterology, Edmonton 2005 (published on CD).
314. **Adams PC**. Hemochromatosis. In Hepatology. Eds. Tom Boyer, T Wright, M Manns, 5th Edition. Saunders Elsevier Science, Philadelphia 2006;1239-1256.
315. **Adams PC**. Iron Overload Diseases. Diseases of the Liver and Biliary System. Sherlock, James Dooley, A Burroughs, J Heathcote, A Lok, Eds. 11th Edition 2008;808-814.
316. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy, Ed. Rakel RE, WB Saunders, Philadelphia 2006;527-530.
317. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy, Ed. Rakel RE, WB Saunders, Philadelphia 2010;437-440.
318. **Adams PC**. Hemochromatosis. In Hepatology. Eds. Tom Boyer, A Sanyal, M Manns, 6th Edition. Saunders Elsevier Science, Philadelphia 2011;1127-1144.
319. **Adams PC**. Iron Overload Diseases. Diseases of the Liver and Biliary System. Sherlock, James Dooley, A Burroughs, J Heathcote, A Lok, Eds. 12th Edition 2011;521-533.

320. **Adams PC** Hemochromatosis. In: First Principles of Gastroenterology. Eds. Thomson A.B.R., Shaffer E.A. 6th Edition, Canadian Association of Gastroenterology, Edmonton 2011;451-455.
321. Jeffrey G, **Adams PC**. Hemochromatosis. Evidence-Based Gastroenterology. 3rd Edition Eds. JWD McDonald, A Burroughs, B Feagan. Wiley Books (London) 2010;484-492.
322. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy 2015, Ed. Kellerman R, WB Saunders, Philadelphia 2014;839-840.
323. **Adams PC**. Hemochromatosis. Textbook of Gastroenterology, Yamada T et al. 6th Edition, eds. Wiley Blackwell 2016;2015-2022.
324. **Adams PC**. Atlas of Gastroenterology, Yamada T et al., 5th Edition, Wiley Blackwell 2016;415-418.
325. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy 2016, Ed. Kellerman R, WB Saunders, Philadelphia 2016;845-846..
326. Zoller H, **Adams PC**. Iron Overload Diseases. Diseases of the Liver and Biliary System. Sherlock, James Dooley, Eds. 13th Edition 2017 (in press).
327. **Adams PC** Current therapy of hemochromatosis. In: Conn's Current Therapy 2018, Ed. Kellerman R, WB Saunders, Philadelphia 2018; (in press).
328. Jeffrey G, **Adams PC**. Hemochromatosis. Evidence-Based Gastroenterology. 4th Edition 2017 (in press).

Non-medical publications

Adams PC. Jazz at the New School. CODA Magazine 1997;274:5.

Patent Applications

U.S. Patent application 09/439,378 – filed November 15, 1999 – 5569A polymorphism of *HFE* gene

Educational Highlights

Highest rated oral presentation, American Association for the Study of the Liver Annual Meeting, Postgraduate Course, San Francisco 2008

Department of Medicine – Postgraduate Prize for Resident Research Supervisor – 2005

Teaching Prize – GI and Nutrition Curriculum Development – 2nd Year Medicine, August 2005

Teaching Prize for Best Presentation Continuing Medical Education Day in Gastroenterology, Sheraton Hotel, London, March 1993

Teaching Prize for Best Presentation Continuing Medical Education Day in Gastroenterology, Delta Armouries Hotel, London, April 1996

Teaching Prize for Best Presentation Continuing Medical Education Day in Gastroenterology, LHSC-UH, London, December 1997

Nominated for CME Teaching Award of Excellence 1996, 1997

Canadian Hepatitis Education Council - Development of national teaching modules for Hepatitis B and C in conjunction with Science and Medicine Canada.

Mentor – Clinician Investigator Trainee Association of Canada, BearTracks Mentorship Program (Trinity College School, 2 students)

Research supervisor

Research GI fellow - Jordan Golubov, M.D. - recipient UWO resident research prize and Physician Services Incorporated (PSI) Foundation research prize - May 1990

Research GI fellow - Ed Lin, M.D. - recipient PSI Foundation research prize - May 1991

Research GI fellow - Gordon Bierbrier, M.D. - recipient PSI Foundation resident research grant (\$14,500), UWO Resident Research Prize, CAG resident research prize, CSCI Research Prize, PSI Foundation research prize - 1993.

Research Hepatology fellow - Mark Levstik, M.D. - recipient Canadian Association for the Study of the Liver Fellowship (external award - \$55,000) - July 1996

Sabbatical - Gary Jeffrey, M.D., Senior Lecturer, University of Western Australia, Perth - March 1998 - January 1999. 6 publications including Nature Genetics during sabbatical.

Research Pathology fellow – Ken Alanen – recipient of M. Smout Pathology award for resident research, PSI Foundation research grant – July 1999

Research Supervisor – Naveen Arya – R2 Internal Medicine, 2 month research elective – publication, presentation at Canadian Digestive Disease Week, Recipient PSI Foundation Resident Research Prize – June 2000

Research Supervisor – John Wojcik – R2 Internal Medicine, 2 month research elective, presentation at Canadian Digestive Disease Week. **Winner of national prize, Thomson-Williams Award for best research publication in the the Canadian Journal of Gastroenterology 2002.**

Research Supervisor – Jerry McGrath – R2 Internal Medicine, Research elective, Prize for best oral presentation at Canadian Digestive Disease Week, Fellows Course, Research Prize, PSI Foundation of Ontario

Research Supervisor – Melanie Beaton – R2 Internal Medicine, Research elective - presentation at Canadian Digestive Disease Week, Montreal, and Digestive Disease Week, San Francisco. Awarded top Faculty research prize by the Canadian Society for Clinical Investigation. Best oral presentation – Resident Research Day – Department of Medicine

Research Supervisor – Cory Yamashita – R2 Internal Medicine, Research elective – oral presentation at Digestive Disease Week 2003, Orlando. Resident Research Day Prize – Department of Medicine, May 2003, PSI Foundation Resident Research Prize June 2003.

Research Supervisor – Karen Wong – R2 Internal Medicine, Research elective – Resident Research Day Prize, Department of Medicine, May 2004

Research Supervisor – Adrian Lazarescu – R2 Internal Medicine, Research elective – Resident Research Day Presentation, Department of Medicine, May 2004

Research Supervisor – Patrick Tan – R2 Internal Medicine, Research elective – Resident Research Day Presentation, Digestive Diseases Week presentation May 2004, New Orleans.

Research Supervisor – Karen Wong – R4 Gastroenterology, Research elective – **Winner of national prize, Thomson- Williams Award for best research publication in the the Canadian Journal of Gastroenterology 2006.**

Research Supervisor – Jose Nazareno – R4 Gastroenterology, Research elective – presented at Digestive Disease Week, Los Angeles and publication in Can J Gastro 2007.

Research Supervisor – Nitin Sarin – R4 Gastroenterology, **Winner of national prize, Thomson-Williams Award for best research publication in the Canadian Journal of Gastroenterology 2010.**

Research Supervisor - Caitlin Symonette - UWO Medical Student - Presented at Canadian Digestive Diseases Week, and published her research in the Can J Gastroenterology 2011.

Research Supervisor – Jeff So – R4 Gastroenterology. Presentation at the American Association for the Study of the Liver Annual Meeting, Boston, October 2010, Digestive Diseases Week, Chicago May 2011 and **winner of the Roche UWO Prize in Liver Research 2011**

Research Supervisor - Andrew Lim - UWO Medical Student, Research project was presented at the American Association of the Study of Liver Diseases Annual Meeting, Washington DC, November 2013 and is in press Can J Gastro Hep 2014.

Research Supervisor - Alexander Levstik - UBC Science Student - GNPAT mutation in hemochromatosis (presentation at CDDW Banff March 2015 and AASLD San Francisco November 2015).

Research Supervisor – Justin Cottrell, UWO Medical Student, Schulich Professionalism Award 2017, Ontario Medical Association Award 2016

Summary of Research Trainees – 12 National Prizes, 9 UWO Prizes

National and International Course Organizer

Chair – AASLD Postgraduate Course – Screening in Liver Diseases – Digestive Diseases Week, Orlando, Florida May 2003

Co-Chairperson - Hemochromatosis: Molecular medicine at the crossroads. National Institute of Health Conference, Bethesda, Maryland, May 1998

Co-Director – Postgraduate Course, Canadian Digestive Disease Week, Montreal 2001

Director – Canadian Liver Foundation Course on Liver Diseases – Alaska, July 2002

Leadership Courses

International

Harvard School of Public Health. Leadership Strategies for Evolving Health Care Executives. Boston – Oct 31 – Nov 5, 2010.

National

Canadian Conference on Physician Leadership: How Effective Leaders Solve Complex Problems (CMA/CPSE)– Toronto – April 22-24, 2010

Dialogue: The language of complex systems (CMA/PMI) – Toronto – April 21, 2010

Local

Mentoring Faculty: How we can all succeed – University of Western Ontario, October 14, 2010

Principles of Negotiation – University of Western Ontario – January 22, 2010

Crucial Conversations (VitalSmarts), London Health Sciences Centre – April 2009

Crucial Accountability (VitalSmarts), London Health Sciences Centre - June 2014

Ivey School of Business University of Western Ontario – Emerging Leaders – January 27-28, 2009

Building Collaborative Relationships, Coalitions and Strategic Partnerships, Schulich School of Medicine, January 29, 2016

Financial Analysis and Planning for Physician Leaders. Ivey Business School, Western University, Jan 7, 14 - 2017

Guest Lecturer

Visiting Speaker

Canada - University of Alberta (2), University of Toronto (3), Queen's University (2), Dalhousie University (2), University of British Columbia (2), Laval University, University of Ottawa (2), McGill University, University of Manitoba, University of Montreal, Memorial University, McMaster University

Sheila Sherlock Visiting Professorship – University of Toronto – March 2010

United States - Harvard University (2), Yale University, National Institute of Health (NIH), University of Massachusetts, University of Oregon, University of Wisconsin, St. Louis University, Scripps Clinic (LaJolla, CA), University of Colorado, Mount Sinai Hospital School of Medicine (New York City), Kaiser Permanente, Honolulu, Howard University (Washington DC), Virginia Commonwealth University, SUNY Buffalo, Dartmouth University, University of Vermont, University of Michigan, University of North Carolina, University of Minnesota, University of Rochester, University of Iowa

Australia - University of Queensland (3), Westmead Hospital, Sydney, University of Western Australia (2),

Europe - University of Southampton (England), Universite de Rennes (France), University of Vienna, University of Dublin

Asia - Second Medical College of Shanghai (China).

National and International Conference Speaker

United States

Hemochromatosis - Diagnosis and Management, Jeffress Palmer Memorial Lectureship, University of North Carolina, Chapel Hill, NC, October 29, 2015

Epidemiology and Laboratory Testing for Hemochromatosis. International Society for Laboratory Hematology, Chicago, IL, May 19, 2015.

Cecil J Watson Memorial Lectureship, University of Minnesota, Minneapolis, MN. Prediction of hemochromatosis. June 19, 2014.

The Ironic Quartet. GI Grand Rounds, University of Minnesota, Minneapolis, MN, June 19, 2014.

Prediction of Hemochromatosis. Rochester General Hospital, University of Rochester, Rochester, New York, April 4, 2014.

Medical Grand Rounds, University of Iowa, Iowa City, IA. Searching for Hemochromatosis. March 7, 2014.

The Ironic Quartet. Joyce Miller Lectureship, University of Iowa, Iowa City, IA. Searching for Hemochromatosis. March 7, 2014.

Genetic Testing – Meet the Professor - American Association for the Study of Liver Diseases Postgraduate Course, November 9, 2012, Boston, MA

Genetic and Genomic Toolkit for the Practicing Hepatologist – Genetic testing for hemochromatosis and other Mendelian disorders. American Association for the Study of Liver Diseases Postgraduate Course, November 9, 2012, Boston, MA

Pathogenesis and Genetics of Hemochromatosis – American Association for the Study of Liver Diseases Postgraduate Course, October 31, 2010, Boston, MA

Hemochromatosis – University of Michigan, Ann Arbor, May 14, 2010

Diagnostic tests for iron overload – Digestive Diseases Week, May 4, 2010, New Orleans, LA

The interplay between genetic modifiers and iron status in determining serum transferrin levels. Iron Status: A pathway analysis in multiple ethnicities. Genetic Epidemiology Research Institute, Newport Beach, CA, University of California at Irvine, April 16, 2010.

Center for Disease Control, Atlanta, GA – Clinical Screening of Iron Overload Related Disease – September 25, 2009

American Association for the Study of Liver Diseases Annual Meeting Postgraduate Course – Hemochromatosis, Hepatology's Most Common Liver Disease – San Francisco, CA, October 31, 2008

Hemochromatosis 2008 – University of Vermont, Burlington, Vermont, June 13, 2008

Grace Lectureship, Brigham and Women's Hospital, Harvard University – Hemochromatosis, May 14, 2008

American Association for the Study of Liver Diseases Annual Meeting Postgraduate Course – Diagnosis and Screening for Iron Overload – Boston, MA, November 3, 2007

Hans Fromm Memorial Lecture, Hemochromatosis – Dartmouth College, New Hampshire, October 4, 2007

Genotype/Phenotype correlations in hemochromatosis – AASLD Clinical Research Conference – Sept 7 – 9, 2007, Atlanta, GA

The HEIRS Study – East Coast Iron Club, Wake Forest University, Winston-Salem, NC, November 17, 2006

Hemochromatosis 2006 – Duke University, NC – September 8, 2006

Hemochromatosis – Genetic Tales from Celtica – SUNY Buffalo, New York, November 4, 2005

Hemochromatosis – Distinguished Lecturer Series, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), National Institute of Health (NIH), Bethesda, Maryland, October 20, 2005

Population Screening for Hemochromatosis, Distinguished Lecturer Series – Yale University, New Haven, CT, February 16, 2005.

Hemochromatosis: Meet the Professor - American Association for the Study of Liver Diseases Annual Meeting, October 30, Boston 2004

Hemochromatosis: Diagnosis and management - American Association for the Study of Liver Diseases Annual Meeting, October 26, Boston 2003

Non-*HFE* Iron overload - American Association for the Study of Liver Diseases Annual Meeting, Postgraduate Course, October 24, Boston 2003

Course Director and speaker – Screening for Liver Diseases – Digestive Diseases Week, Orlando, Florida, May 18, 2003.

Hemochromatosis: Genetic diagnosis and management - American Association for the Study of Liver Diseases Annual Meeting, November 2, Boston 2002

Screening for Hemochromatosis - American Association for the Study of Liver Diseases Annual Meeting, Early Morning Workshop Leader, November 3, Boston 2002

Hemochromatosis – Meet the Professor – Digestive Diseases Week – San Francisco, May 22, 2002, San Francisco, CA.

Hemochromatosis - American Association for the Study of Liver Diseases Annual Clinical Meeting, March 2, Los Angeles 2001

Population screening for hemochromatosis -(American Association for the Study of Liver Diseases Annual Meeting, Dallas 1999)

Screening for genetic liver diseases -(Meet the Professor, American Association for the Study of Liver Diseases Annual Meeting, Dallas 1999)

Diagnosis and management of hemochromatosis - American Society of Hematology Annual Meeting, December 6, 1998, Miami Beach, Florida.

Hemochromatosis - Meet the Professor Symposium, (American Association for the Study of Liver Diseases Annual Meeting, Chicago 1998)

Hemochromatosis: Molecular medicine at the crossroads. National Institute of Health Conference (chairperson and speaker), Bethesda, Maryland, May 1998

Hemochromatosis: Clinical aspects of genetic testing - Digestive Disease Week - Meet the Professor, New Orleans, May 1998.

Hemochromatosis - Mayo Clinic Hepatology Update, Orlando, March 19 - 21, 1998

Hemochromatosis – Mayo Clinic Hepatology Update, Minneapolis, Sept 19, 1997

Genotypic / phenotypic correlations in hemochromatosis - Center for Disease Control, Atlanta, GA - February 1998

Hemochromatosis - University of North Dakota, Fargo, North Dakota, Sept 17, 1997

Population screening for hemochromatosis - University of North Dakota, Fargo, North Dakota, Sept 17, 1997

Screening models and decision analysis for hemochromatosis – Co-chairman conference - Iron overload, public health and genetics conference, March 3, 1997, Centre for Disease Control, Atlanta

Genetics of hemochromatosis - Digestive Disease Week 1996 (American Gastroenterology Association Symposium Speaker, San Francisco,CA)

Hemochromatosis - Meet the Professor Symposium, (American Association for the Study of Liver Diseases Annual Meeting, Chicago 1994)

Hemochromatosis - Symposium - Recent advances in hemochromatosis (American Association for the Study of Liver Diseases Annual Meeting, Chicago 1996)

Employment after liver transplantation - International Conference of Rehabilitation Medicine Washington, D.C., April 1995

Other international presentations

Chasing the ferritin - high and why ? Westmead Hospital, Sydney, Australia, May 21, 2014

Prediction of hemochromatosis. Sydney Liver Group, Sydney, Australia, May 21, 2014

Prevalence, penetrance and Clinical Expression of Hemochromatosis. Hemochromatosis Conference. Austin Hospital, Melbourne, Australia, May 18, 2014

Prediction of hemochromatosis. Hemochromatosis Conference. Charles Gardiner Hospital, Perth Australia, May 16, 2014

An approach to the diagnosis of iron overload in Asian patients. Royal Brisbane Hospital, Australia, May 12, 2014

Building the academic health care network. Customs House, University of Queensland, Brisbane, Australia, October 15, 2011.

In search of an academic career. Princess Alexandra Hospital, Brisbane, Australia, October 14, 2011

The ironic quartet. Princess Alexandra Hospital, Brisbane, Australia, October 13, 2011

The challenges of genetic discrimination. Royal Brisbane Hospital Symposium, October 10, 2011, Brisbane, Australia

Current trends in health education in North America. Royal Brisbane Hospital Symposium, October 12, 2011, Brisbane, Australia

Elevated serum ferritin in Asian participants in the HEIRS Study. Kyoto Prefectural University of Medicine, Kyoto, Japan, March 18, 2011 (cancelled due to earthquake).

Do all hemochromatosis patients have the same ancestral origin? Bioiron Conference, June 11, 2009, Porto, Portugal.

Phase I/II Study of Deferasirox in the treatment of hereditary hemochromatosis. European Hematology Association. June 5, 2009, Berlin, Germany.

Asian iron overload in the HEIRS Study – Asian-Pacific Association for the Study of the Liver Annual Meeting – March 30, 2007, Kyoto, Japan

Screening for hemochromatosis - Irish Gastroenterology Association Annual Meeting, Limerick, Ireland, June 10, 2005

Hemochromatosis – Mater Hospital, Dublin, Ireland, June 8, 2005

Clinical expression of Hemochromatosis, a gene in search of a disease? – Bioiron Meeting, Prague, Czech Republic, May 2005

Genetic Hemochromatosis – AKH Hospital, University of Vienna, Austria, May 2005

Population screening for hemochromatosis – State of the Art Lecture – Bushell Lecturer, Australian Gastroenterology Week, Brisbane, Australia October 2004

Hepatic Iron and Liver Disease – State of the Art Lecture – Bushell Lecturer, Australian Gastroenterology Week, Brisbane, Australia October 2004

HFE Hemochromatosis – A clinical enigma – State of the Art Lecture – Bushell Lecturer, Australian Gastroenterology Week, Brisbane, Australia October 2004

Clinical diversity of phenotypic expression of hemochromatosis – State of the Art Lecture – Bushell Lecturer, Australian Gastroenterology Week, Brisbane, Australia October 2004

Population screening for hemochromatosis – searching for genes, iron or disease ? – Bioiron 2001 – Cairns, Australia – August 2001

State of the Art Lecture – Haemochromatosis – Five years after the gene – British Society of Gastroenterology – Glasgow, Scotland, March 20, 2001

Hemochromatosis – Genetic tales from Celtica – University of Queensland, Brisbane, Australia, December 1999

Genetics and Hemochromatosis – University of Western Australia, Perth, Australia – December 1999

Chairman, International Consensus Group on Population Screening for Hemochromatosis (CDC, NIH, EASL), Bioiron 99, Sorrento, Italy, May 1999

Miscellaneous iron overload syndromes. World Congress of Gastroenterology, Vienna, Austria, September 1998.

Iron overload in alcoholic liver disease and viral hepatitis. European Association for the Study of Liver Disease (EASL) Annual Postgraduate Course, Lisbon, Portugal, April 1998

Screening for Hemochromatosis – Annual meeting Swiss Society of Gastroenterology and Hepatology, Lausanne, Switzerland, Oct 3, 1997

Cost Benefit of Population Screening for hemochromatosis - World Health Organization (WHO) Symposium - Prevention and Control of hemochromatosis' - Saint Malo, France, June 18th, 1997.

Diagnostic Criteria of Genetic Hemochromatosis - International Symposium on Iron in Biology and Medicine - St. Malo, France June 16th. 1997.

Canada

Kananaskis (Alberta), Banff (CDDW X 6), Victoria (BC), Chanteclair (Quebec), Quebec City (5), Ottawa (X 3), Kitchener, Oshawa, Cambridge, Windsor, Peterborough, Niagara on the Lake (Ontario), Montreal (CDDW X 3), Toronto, Vancouver, Edmonton, Winnipeg, Kingston, Halifax

External Reviewer

Editor-in-Chief – Canadian Journal of Gastroenterology April 2005 – June 2010

Associate Editor – Canadian Journal of Gastroenterology 2003 - 2004

Editorial Board – Hepatology, Canadian Journal of Gastroenterology, Liver International

Journals – New England Journal of Medicine, PNAS, Lancet, British Medical Journal, Hepatology, Gastroenterology, Gut, American Journal of Physiology, Digestive Diseases and

Sciences, Journal of Hepatology, American Journal of Gastroenterology, Canadian Journal of Gastroenterology, American Journal of Medicine, JAMA, Journal of Rheumatology, Canadian Medical Association Journal, Clinical and Investigative Medicine, American Family Physician, Molecular Metabolism and Genetics, Liver Transplantation, Scandinavian Journal of Gastroenterology, European Journal of Haematology, American Journal of Transplantation, Alimentary Pharmacology and Therapeutics

Canadian Institute of Health Research – Experimental Medicine Grant Review Committee 2002, Project Grant Review Committee 2017

Grants - National Institute of Health (NIH), CIHR, Medical Research Council of Australia, Wellcome Trust (UK), Health Research Board (Ireland), Alberta Heritage Foundation for Medical Research, Ministry of Health of Ontario, Canadian Liver Foundation, Heart and Stroke Foundation, BC Health, University of Texas.

Abstracts - Digestive Disease Week 1997, 1998, 1999 American Association of Liver Diseases meeting 1997, 1998, Canadian Association for the Study of Liver Disease meetings, Canadian Digestive Disease Week, Gastro 99 meeting, Chair Liver and Nutrition Review Committee, Digestive Diseases Week, Chicago 2014

Active UWO/LHSC Committees and Appointments

Schulich School of Medicine Research Task Force – September 2010
 Team Leader – Clinical Teaching Unit, GI Team, University Hospital
 Department of Medicine Executive Committee
 Division of Gastroenterology Program Committee
 Lawson Research Institute – Clinical Research Advisory Committee April 2012

External Appointments

Canadian Association of Gastroenterology Governing Board – 2005 -2009
 American Association for the Study of the Liver – International Liason Committee 2005
 Canadian Association for the Study of the Liver (CASL) - President 2000 - 2002
 Canadian Association for the Study of the Liver (CASL) - Vice-President -1998 - 1999
 Canadian Association for the Study of the Liver (CASL) -Chairman,Education Committee 1995 – 1998
 Canadian Association for the Study of the Liver (CASL) –Councillor, March 2010 -
 Canadian Liver Foundation – Chairman, Medical Advisory Committee – 2001 -
 Canadian Liver Foundation - Chairman, Education Committee 1995-1998.
 Canadian Liver Foundation - Medical Advisory Committee 1998 - 2001
 Canadian Liver Foundation – Board of Directors 1999-2000
 Canadian Liver Foundation - Graduate Students Award Committee 1995
 Canadian Liver Foundation - Summer Student Awards Committee
 Canadian Liver Foundation Liver Letter - Editorial Committee
 Canadian Hemochromatosis Society - Chief Medical Advisor, Board of Directors
 International Liver Transplantation Society - Program Committee, Toronto 1993
 Chairman, Liver Diseases Section, Royal College of Physicians and Surgeons Plenary Session, Ottawa 1992, Vancouver 1993, Toronto 1994
 Royal College of Physicians and Surgeons Program Committee Reviewer
 Canadian Hepatitis Education Council 1995 - 1998
 Canadian Association of Gastroenterology Education Committee
 Canadian Digestive Disease Week – Organizing Committee 2000 – 2002

Canadian Association of Gastroenterology – Chair, Hepatobiliary and liver transplantation committee – 2006

External Consultant

Advisor to University of Queensland Medical School to the development of a Health Sciences Complex - Public Lecture summarizing findings was delivered at Government House, Brisbane, October 15, 2011

Strategic Advisor to Queens University on CFI Grants in Gastroenterology which were then approved for funding in 2013.

Extracurricular Interests

Performing jazz musician – drums, vibraphone (<http://pauladams.ca/jazz.html>)

Jazz collector, musicologist

Film maker

World travel